Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women
DURHAM, N.C., July 28, 2022 (GLOBE NEWSWIRE) — Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (Read More